Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Combat Meth Act Compliance Can Trip Up Drug Retailers

This article was originally published in The Tan Sheet

Executive Summary

Complying with the nationwide limit the Combat Meth Act set on sales of pseudoephedrine-containing OTCs is simpler than handling separate state or local laws, but retailers' responsibilities under the act have not been easily met, the head of a Montana pharmacy chain tells the Senate Finance Committee

You may also be interested in...



States’ Limits On OTC Dextromethorphan Sales Could Force Congress’ Hand

US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.

States’ Limits On OTC Dextromethorphan Sales Could Force Congress’ Hand

US House legislation banning the sale of DXM OTCs to consumers under age 18 likely stands the same chance right now as previous versions that have failed, but CHPA expects an increasing number of state laws could spur future action.

Proposed Combat Meth Compliance Fee Would Be Waived For Many Retailers

Businesses already paying to support the Drug Enforcement Administration's Diversion Control Program would be exempt from paying an additional fee to certify they have trained employees on compliance with the Combat Meth Act, DEA says in a proposed rule

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS100924

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel